High Grade Serous Ovarian Cancer
13
6
7
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
7.7%
1 terminated out of 13 trials
50.0%
-36.5% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (13)
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Minimal Residual Disease in Solid Malignancies
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma
"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
Expanded Access to Veliparib
miRNAs in High Grade Serous Ovarian Cancer
NUVOLA TRIAL Open-label Multicentre Study
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors